Cas:420137-14-0 3-Benzyloxypyrrolidine manufacturer & supplier

Chemical Name:3-Benzyloxypyrrolidine

CAS.NO:420137-14-0

Synonyms:Pyrrolidine, 3-(phenylmethoxy)-;3-(Benzyloxy)pyrrolidine

Molecular Formula:C₁₁H₁₅NO

Molecular Weight:177.243

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:269.2±33.0 °C at 760 mmHg

Density:1.1±0.1 g/cm3

Index of Refraction:1.546

PSA:21.26000

Exact Mass:177.115356

LogP:1.53

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Pyrrolidine, 3-(phenylmethoxy)- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-(Benzyloxy)pyrrolidine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Pyrrolidine, 3-(phenylmethoxy)- Use and application,Pyrrolidine, 3-(phenylmethoxy)- technical grade,usp/ep/jp grade.

Related News: A possible reason for this is that developments within the biocatalysis field have fast outpaced existing knowhow, leaving some pharmaceutical companies unaware of the vast range of options available. Keeping abreast of both current and emerging developments within the field of biocatalytic processing is key when it comes to maintaining a competitive edge. 3(2H)-Pyridazinone, 5-chloro-2-methyl-6-nitro-4-(2-pyrimidinylthio)- manufacturers To make Zynteglo, the stem cells taken from the patient’s blood are modified by a virus that carries working copies of the beta-globin gene into the cells. 3,5-bis(4-methylphenyl)-2-aza-2,4-heptadiene suppliers MG is a “serious, lifelong disease with life-threatening manifestations, and most patients do not achieve treatment goals with conventional therapy,” the report said. Tris-(1H,1H,7H-dodecafluor-heptyloxy)-methyl-silan vendor & factory To make Zynteglo, the stem cells taken from the patient’s blood are modified by a virus that carries working copies of the beta-globin gene into the cells. ,MG is a “serious, lifelong disease with life-threatening manifestations, and most patients do not achieve treatment goals with conventional therapy,” the report said.